Protein Engineering for HIV Therapeutics
DOI link for Protein Engineering for HIV Therapeutics
Protein Engineering for HIV Therapeutics book
It has been more than 25 years since the ﬁrst cases of AIDS were described, and even though the etiological agent responsible, HIV, was identiﬁed early in 1983, we are still in the midst of a global pandemic [1-3]. The development of speciﬁc inhibitors aimed at essential steps for viral infectivity and replication is a rapidly expanding ﬁeld. The ﬁrst therapeutic attempts at controlling replication and limiting transmission were focused primarily on the unique enzymes encoded by HIV: reverse transcriptase (RT), protease (PR), and more recently integrase (IN) . The focus has broadened to include strategies that target structural proteins of HIV, and speciﬁcally the mechanisms used by HIV to infect a cell and replicate.